Life Balance

SAINT trial: two labour drugs show no clear benefit for first-time mothers

By Vikram JoshiLife Balance Correspondent, Peepals Shakti
WhatsAppX
Representative image: pregnant woman hospital bed

Representative image: 2147792 / Pixabay

A BMJ trial of 2,963 first-time mothers in Norway, out on 19 November, found no clear benefit from hyoscine butylbromide or sodium bicarbonate after induction.

SAINT trial: what happened

Two inexpensive drugs that some maternity units use to help labour progress did not clearly increase natural births among first-time mothers whose labour was induced, according to a large Norwegian trial published in The BMJ on Thursday, 19 November 2026. The SAINT trial enrolled 2,963 first-time mothers at 11 hospitals in Norway and tested hyoscine butylbromide, a muscle relaxant given by injection, and sodium bicarbonate, an antacid taken by mouth, against dummy treatments. The authors concluded that their findings do not support routine use of either drug during labour after induction.

SAINT trial: key facts

  • Study: SAINT (Safe Induction of Labour Trial), a randomised, placebo-controlled trial published in The BMJ on 19 November 2026.
  • Participants: 2,963 first-time mothers, average age 31, whose labour was induced, at 11 Norwegian hospitals.
  • Groups: both drugs; sodium bicarbonate alone; hyoscine butylbromide alone; or two placebos (dummy treatments).
  • Dosing: each drug was given every four hours, up to three doses, from the start of active labour.
  • Main outcome: spontaneous vaginal birth, meaning birth without forceps, vacuum or caesarean section.
  • Results: 57% (422 of 741) with both drugs, 61% (445 of 734) with bicarbonate alone, 61% (449 of 741) with hyoscine butylbromide alone and 56% (422 of 747) with placebos.
  • None of the differences met the trial's preset threshold for statistical significance; serious adverse events were similar across groups.

SAINT trial: why it matters

Induction means starting labour artificially, with medicines or other methods, instead of waiting for it to begin on its own. For first-time mothers, a birth without forceps, vacuum or caesarean section is the outcome most hope for, and doctors have looked for simple, cheap drugs that might make it more likely. Hyoscine butylbromide and sodium bicarbonate were the two the Norwegian team chose to test. A rigorous trial was needed to see whether they actually help.

This trial is large and carefully designed: women were randomly assigned to one of four groups, and the double-blind design meant that neither they nor their carers knew who received active drugs. That makes its finding of no clear benefit important. The researchers did not rule out a small benefit, and the single-drug groups did slightly better than the placebo group, but the differences were too small to be confident they were real rather than chance.

There are limits. The drugs were given at the start of active labour regardless of how early labour had gone, so the results may not apply to other timings or doses. The trial took place in Norway's hospital system, and results elsewhere, including in India, could differ. The findings concern a routine practice, not any individual woman's care, and decisions in labour remain for mothers and their doctors and midwives.

For women planning a first birth, the practical point is about questions, not treatments. Knowing that a commonly suggested add-on has not shown a clear benefit in a strong trial can help expectant parents discuss options with their care team.

Peepals calculation: the single-drug groups had spontaneous births in about 60.6% of cases (449 of 741 and 445 of 734), against 56.5% with placebo (422 of 747), a gap of about 4 percentage points that the trial did not judge to be significant. The four groups add up to 2,963 women (741 + 734 + 741 + 747). Our calculation from the reported figures.

GroupSpontaneous vaginal birth
Hyoscine butylbromide + sodium bicarbonate422 of 741 (57%)
Sodium bicarbonate alone445 of 734 (61%)
Hyoscine butylbromide alone449 of 741 (61%)
Placebo only422 of 747 (56%)

SAINT trial: impact

Short-term: Hospitals that give these drugs routinely after induction may review the practice in light of the trial. The authors' conclusion is directed at routine use, not at every individual case.

Long-term: The trial adds to the evidence that simple add-on drugs are not a shortcut to fewer assisted births after induction. Researchers may test other timings, doses or approaches to supporting induced labour.

Who is affected: First-time mothers facing induction of labour, obstetricians and midwives, and hospitals that set maternity care protocols.

SAINT trial: key takeaway

If you are expecting a first baby and may be induced, ask your doctor or midwife what support they plan during labour and why; this trial found no clear evidence that these two add-on drugs help.

SAINT trial: questions and answers

What did the SAINT trial test?

Whether hyoscine butylbromide, sodium bicarbonate or both, given during labour, increased the chance of a birth without forceps, vacuum or caesarean section in first-time mothers whose labour had been induced.

What did the trial find?

Spontaneous birth rates were 56% with placebo and 57% to 61% with the drugs. None of the differences met the trial's threshold for statistical significance, so the authors found no clear evidence of benefit.

Were the drugs unsafe?

Serious adverse events were similar between the groups, and the coverage reported no treatment-related serious illness.

Do the results apply in India?

The trial was run in 11 Norwegian hospitals, so results in other health systems could differ. It informs routine practice but does not replace advice from a mother's own doctor or midwife.

Disclaimer: Prepared by the Peepals newsroom from publicly available sources with AI assistance. Information is accurate to the best of our knowledge at the time of publication and may change. Images may be representative. Not professional advice. Report an error via our contact page.

#SAINT trial#induction of labour#first-time mothers#The BMJ#hyoscine butylbromide

By Vikram Joshi, Life Balance CorrespondentCovers Life Balance and more for Peepals Shakti. All stories by Vikram Joshi

Your week ahead, every Sunday. Free.

Exam and result dates, IPOs opening, scheme deadlines, government holidays and the RBI decision for the next 7 days, plus the week's top stories. One email a week, unsubscribe in one click.

Vikram Joshi is a pen name of the Peepals Global Editorial Team, which researches, fact-checks and publishes every story. The portrait is an illustration.

Responsible for this story: the Peepals Global Editorial Team, led by editor Prashant Sonar. How we report

More from Peepals Shakti

Your week ahead, every Sunday. Free.

Exam and result dates, IPOs opening, scheme deadlines, government holidays and the RBI decision for the next 7 days, plus the week's top stories. One email a week, unsubscribe in one click.